Halloween has come and gone in the US, and Americans are now gearing up for Thanksgiving and Christmas. But before the holiday season could get underway, the country went through a major political event with far-reaching implications: the midterm elections.As…
BUSINESS
Kissei Launches PIII Study of Oncolytic Viral Therapy for Bladder Cancer in Japan
Kissei Pharmaceutical said on March 24 that it has kicked off the Japan part of the multinational PIII BOND3 study of the oncolytic viral therapy CG0070 for bladder cancer. The company snagged the exclusive development and commercialization rights in March last…
To read the full story
Related Article
BUSINESS
- AstraZeneca’s Etcamah to Hit Japan Market on Nov. 27
November 20, 2026
- J&J’s Icotyde Could Broaden Psoriasis Treatment Options: Expert
November 20, 2026
- Nippon Kayaku to Acquire AstraZeneca’s Zoladex on Dec. 16
November 20, 2026
- Tanabe to Wind Down NeuroDerm, Scrap EU Launch of Parkinson’s Drug
November 19, 2026
- Shionogi Narrows R&D Pipeline to 21 Priority Programs Across 3 Disease Areas
November 19, 2026





